These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 30523414

  • 1. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
    Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y.
    J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
    [Abstract] [Full Text] [Related]

  • 2. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 3. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.
    Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y.
    BMC Nephrol; 2017 Feb 15; 18(1):66. PubMed ID: 28201994
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T.
    Bone; 2014 Feb 15; 59():44-52. PubMed ID: 24184313
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE.
    J Bone Miner Res; 2005 Dec 15; 20(12):2105-15. PubMed ID: 16294264
    [Abstract] [Full Text] [Related]

  • 6. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 15; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 7. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun 15; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 8. Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
    Soen S, Kishimoto H, Hagino H, Sone T, Ohishi H, Fujimoto T, Sasaki E, Tanaka S, Sugimoto T.
    J Bone Miner Metab; 2020 Jan 15; 38(1):86-98. PubMed ID: 31420748
    [Abstract] [Full Text] [Related]

  • 9. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.
    Soen S, Umemura T, Ando T, Kamisaki T, Nishikawa M, Muraoka R, Ikeda Y, Takeda K, Osawa M, Nakamura T.
    J Bone Miner Metab; 2017 Jul 15; 35(4):419-427. PubMed ID: 27565972
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial.
    Fujieda Y, Horita T, Nishimoto N, Tanimura K, Amasaki Y, Kasahara H, Furukawa S, Takeda T, Fukaya S, Matsui K, Tsutsumi A, Furusaki A, Sagawa A, Katayama K, Takeuchi K, Katsumata K, Kurita T, Shane P, Kato M, Oku K, Yasuda S, Takahata M, Iwasaki N, Atsumi T.
    Mod Rheumatol; 2021 May 15; 31(3):593-599. PubMed ID: 32820698
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan 15; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 12. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 15; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group.
    Osteoporos Int; 2015 Nov 15; 26(11):2685-93. PubMed ID: 26001561
    [Abstract] [Full Text] [Related]

  • 14. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.
    Bone; 2012 Sep 15; 51(3):383-8. PubMed ID: 22750403
    [Abstract] [Full Text] [Related]

  • 15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul 15; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 16. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S, Jeglitsch M, McCloskey E.
    Curr Med Res Opin; 2009 Dec 15; 25(12):2951-60. PubMed ID: 19835464
    [Abstract] [Full Text] [Related]

  • 17. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan 15; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 18. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul 15; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.
    Osteoporos Int; 2012 Jan 15; 23(1):267-76. PubMed ID: 21947137
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr 15; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.